Area of research
Reproductive Medicine · Nephrology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Renal Diseases and Glomerulopathies, Cancer, Lipids, and Metabolism, and Hepatocellular Carcinoma Treatment and Prognosis.
Predictions of Response in Non-small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Using Clinical Data, Deep Learning, and Radiomics
ZNF432 suppresses endometrial cancer progression by promoting UPF1 ubiquitination and inducing apoptosis
ENST00000534735 inhibits proliferation and migration, promotes apoptosis and pyroptosis of endometrial cancer via OSBPL3 through APMK/SIRT1/NF-κB pathway
The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology
The role of GADD45G methylation in endometrial cancer: Insights into CDK1/CCNB1 activation and therapeutic opportunities
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab